Stock Fundamentals

Company Information

Company Name
Monte Rosa Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US61225M1027
CIK: 0001826457
CUSIP: 61225M102
Currency: USD
Full Time Employees: 187
Phone: 617 949 2643
Fiscal Year End: December
IPO Date: Jun 24, 2021
Description:

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Address:

321 Harrison Avenue, Boston, MA, United States, 02118

Directors & Officers

Name Title Year Born
Dr. Markus Warmuth M.D. President, CEO & Director 1971
Mr. Philip Nickson J.D., Ph.D. Chief Business & Legal Officer 1979
Mr. Filip Janku M.D., Ph.D. Chief Medical Officer 1974
Mr. Matthew Bowen Corporate Controller & Principal Accounting Officer 1989
Ms. Jennifer Champoux Chief Operating Officer 1972
Mr. Magnus Walter DPHIL Chief Technology Officer NA
Dr. John C. Castle Ph.D. Chief Data & Information Officer 1971
Dr. Sharon Townson Ph.D. Chief Scientific Officer 1975
Mr. Andrew Funderburk Chief Investor Relations and Strategy Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 09, 2026 Philip Nickson N/A Sale 5.85K $17.69 $103.40K
Mar 04, 2026 Edmund Dunn N/A Sale 139.00 $17.96 $2.50K
Mar 02, 2026 Edmund Dunn N/A Sale 536.00 $17.50 $9.38K
Mar 02, 2026 Markus Warmuth N/A Sale 5.47K $17.92 $97.95K
Feb 27, 2026 Edmund Dunn N/A Sale 25.16K $18.10 $455.47K
Jan 07, 2026 Markus Warmuth N/A Sale 5.47K $23.49 $128.40K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
NEA Management Company, LLC 7.69M Mar 31, 2026 9.12% $7.19 0.00%
T. Rowe Price Associates, Inc. 6.72M Mar 31, 2026 7.96% $0.01 31.28%
BlackRock Inc 5.64M Mar 31, 2026 6.68% $0.00 34.84%
TCG Crossover Management, LLC 4.62M Mar 31, 2026 5.48% $2.18 0.00%
Bvf Inc 4.46M Mar 31, 2026 5.29% $2.34 16.29%
Baker Bros Advisors LP 4.35M Mar 31, 2026 5.15% $0.41 0.00%
Suvretta Capital Management, LLC 4.23M Mar 31, 2026 5.01% $1.78 25.80%
Vestal Point Capital LP 3.60M Mar 31, 2026 4.27% $1.66 364.96%
State Street Corp 3.35M Mar 31, 2026 3.97% $0.00 59.15%
Vanguard Group Inc 3.25M Dec 31, 2025 3.85% $0.00 8.62%
BRAIDWELL LP 3.21M Mar 31, 2026 3.80% $1.76 238.13%
Versant Venture Management LLC 3.18M Mar 31, 2026 3.77% $37.00 -27.42%
American Century Companies Inc 2.81M Mar 31, 2026 3.33% $0.02 111.31%
SILVERARC CAPITAL MANAGEMENT, LLC 2.00M Mar 31, 2026 2.37% $3.36 94.55%
Aisling Capital Management LP 1.56M Mar 31, 2026 1.84% $5.37 5.66%
Geode Capital Management, LLC 1.54M Mar 31, 2026 1.83% $0.00 27.88%
Marshall Wace Asset Management Ltd 1.43M Mar 31, 2026 1.70% $0.02 259.29%
Bellevue Group AG 1.25M Mar 31, 2026 1.48% $0.49 0.00%
MPM Oncology Impact Management LP 1.18M Mar 31, 2026 1.39% $1.50 0.30%
Dimensional Fund Advisors, Inc. 1.04M Mar 31, 2026 1.23% $0.00 83.22%

Shares Statistics

Shares Outstanding: 84.48M
Shares Float: 52.94M
% Insiders: 59.10%
% Institutions: 11,310.10%
Short % Float: 17.99%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 2.34M 2.77% ▲ 0.00% Apr 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 2.17M 2.58% ▼ 0.71% Apr 30, 2026
3 Avantis US Small Cap Value ETF 2.05M 2.43% ▲ 0.00% Apr 30, 2026
4 T. Rowe Price Health Sciences 2.00M 2.37% ▲ 2.06% Mar 31, 2026
5 T. Rowe Price New Horizons 1.99M 2.35% ▼ 0.86% Mar 31, 2026
6 US Small-Cap Growth II Equity Comp 1.99M 2.35% ▲ 16.42% Mar 31, 2026
7 HBM Healthcare Investments AG Ord 1.82M 2.16% ▲ 29.61% Mar 31, 2026
8 iShares Russell 2000 ETF 1.43M 1.69% ▲ 0.85% Apr 30, 2026
9 T. Rowe Price New Horizons Tr-A 900.40K 1.07% ▲ 23.03% Mar 31, 2026
10 FIAM Small Cap Core Composite 746.40K 0.88% ▼ 52.82% Dec 31, 2025

Valuation Metrics

Enterprise Value: $1.04B
Trailing P/E: 0.00
Forward P/E: 10.02

Financial Highlights

Market Cap: $1.50B
EBITDA: $-139.94M
Book Value: $6.19
Earnings/Share: $-1.48
Profit Margin: 0.00%
Operating Margin: -1,188.46%
ROA (TTM): -16.41%
ROE (TTM): -32.62%
Revenue (TTM): $42.95M
Revenue/Share (TTM): $0.49
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -95.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 6.12x 0.02x 0.48x N/A -0.10x
2024-12-31 2.40x 0.02x 0.49x N/A -0.05x
2023-12-31 5.07x 0.02x 0.41x N/A -0.02x
2022-12-31 10.79x 0.01x 0.21x -29.86x -0.03x
2021-12-31 20.96x 0.00x 0.05x -67.73x 0.00x
2020-12-31 1.49x 0.00x 1.99x -3,112.22x 0.00x
2019-12-31 2.27x -0.06x 2.10x -7,994.00x -0.10x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GLUE.US!